Brokerages Set Inogen (INGN) PT at $105.20

Shares of Inogen (NASDAQ:INGN) have earned a consensus recommendation of “Buy” from the nine research firms that are currently covering the company, Marketbeat reports. Three investment analysts have rated the stock with a hold recommendation, five have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $111.83.

A number of research analysts recently commented on the company. Piper Jaffray set a $145.00 price target on Inogen and gave the company a “buy” rating in a research note on Saturday. ValuEngine raised Inogen from a “hold” rating to a “buy” rating in a research note on Friday, April 6th. BidaskClub raised Inogen from a “buy” rating to a “strong-buy” rating in a research note on Friday, April 6th. Needham & Company LLC boosted their price target on Inogen from $125.00 to $150.00 and gave the company a “strong-buy” rating in a research note on Wednesday, February 28th. Finally, Zacks Investment Research raised Inogen from a “hold” rating to a “buy” rating and set a $135.00 price target for the company in a research note on Monday, February 19th.

How to Become a New Pot Stock Millionaire

Shares of Inogen stock traded up $3.89 during trading on Thursday, reaching $143.32. The company’s stock had a trading volume of 182,878 shares, compared to its average volume of 143,218. The stock has a market cap of $2,947.02, a PE ratio of 109.49, a PEG ratio of 3.86 and a beta of 1.03. Inogen has a 52 week low of $75.38 and a 52 week high of $143.63.

Inogen (NASDAQ:INGN) last announced its earnings results on Tuesday, February 27th. The medical technology company reported $0.31 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.21 by $0.10. The company had revenue of $63.79 million during the quarter, compared to analysts’ expectations of $62.01 million. Inogen had a net margin of 8.42% and a return on equity of 13.47%. equities analysts anticipate that Inogen will post 1.6 EPS for the current year.

In related news, EVP Matt Scribner sold 2,500 shares of the business’s stock in a transaction dated Thursday, March 15th. The stock was sold at an average price of $127.95, for a total value of $319,875.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Heather D. Rider sold 5,222 shares of the business’s stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $131.13, for a total value of $684,760.86. Following the completion of the transaction, the director now directly owns 3,222 shares of the company’s stock, valued at approximately $422,500.86. The disclosure for this sale can be found here. In the last ninety days, insiders sold 112,218 shares of company stock valued at $13,570,316. 5.29% of the stock is owned by insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. BlackRock Inc. raised its stake in Inogen by 4.0% during the fourth quarter. BlackRock Inc. now owns 2,306,534 shares of the medical technology company’s stock worth $274,662,000 after acquiring an additional 87,737 shares in the last quarter. Brown Capital Management LLC raised its stake in Inogen by 1.8% during the fourth quarter. Brown Capital Management LLC now owns 2,260,706 shares of the medical technology company’s stock worth $269,205,000 after acquiring an additional 40,994 shares in the last quarter. Rockefeller Financial Services Inc. raised its stake in Inogen by 0.9% during the fourth quarter. Rockefeller Financial Services Inc. now owns 301,499 shares of the medical technology company’s stock worth $35,903,000 after acquiring an additional 2,729 shares in the last quarter. Wells Fargo & Company MN raised its stake in Inogen by 15.7% during the third quarter. Wells Fargo & Company MN now owns 300,025 shares of the medical technology company’s stock worth $28,533,000 after acquiring an additional 40,798 shares in the last quarter. Finally, Fred Alger Management Inc. raised its stake in Inogen by 7.9% during the fourth quarter. Fred Alger Management Inc. now owns 248,232 shares of the medical technology company’s stock worth $29,559,000 after acquiring an additional 18,269 shares in the last quarter. 98.97% of the stock is owned by hedge funds and other institutional investors.

WARNING: This report was reported by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this report on another publication, it was illegally copied and republished in violation of international trademark & copyright laws. The original version of this report can be viewed at https://sportsperspectives.com/2018/04/17/brokerages-set-inogen-ingn-pt-at-105-20.html.

About Inogen

Inogen, Inc, a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. The company's oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.

Analyst Recommendations for Inogen (NASDAQ:INGN)

Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply